Al-Masoodi Bodoor Ali Hussen, Reem Alariqi, Bahaj Saleh S, Al-Haimi Raja M, Al-Shamahy Hassan A, Abuasba Nagib, Al-Shawkany Abdu-Raoof Mohammad, Kumal Jay Prakash Prasad
Medical Laboratory Department, Faculty of Medical Sciences, Sana'a University, Sana`a, Yemen.
College of Veterinary Medicine, Sana`a University, Sana`a, Yemen.
IJID Reg. 2022 Sep 20;5:141-145. doi: 10.1016/j.ijregi.2022.09.004. eCollection 2022 Dec.
Occult hepatitis B virus infection (OBI) is a challenging entity. Due to the increase in invasive procedures, blood transfusions, and difficulties in diagnosing OBI, patients are more likely to acquire OBI. This cross-sectional study was conducted to assess the prevalence of OBI by hepatitis B virus (HBV)-DNA detection, the prevalence of HBV infection by total hepatitis B core antibody (HBcAb) detection, and the potential risk factors for HBV infection in patients receiving haemodialysis regularly.
This study included 80 patients receiving haemodialysis regularly, without acute or chronic HBV infection. They were selected from the dialysis units in Sana'a city, Yemen from June 2016 to June 2017. Patients who were positive for hepatitis B surface antigen and hepatitis B surface antibody were excluded from this study. Blood samples were taken prior to each haemodialysis session, and serological markers of HBV were included. HBcAb was measured by enzyme-linked immunosorbent assay, and HBV-DNA was measured by polymerase chain reaction.
HBV-DNA was detected in four patients (5%) and HBcAb was detected in 38 patients (47.5%). There was a significant association between HBV-DNA and HBcAb in patients receiving haemodialysis regularly.
Patients who test positive for HBcAb should undergo additional HBV-DNA testing to allow accurate HBV screening and prevent infection of other patients.
隐匿性乙型肝炎病毒感染(OBI)是一个具有挑战性的实体。由于侵入性操作、输血的增加以及OBI诊断的困难,患者更易感染OBI。本横断面研究旨在通过检测乙型肝炎病毒(HBV)DNA评估OBI的患病率,通过检测总乙型肝炎核心抗体(HBcAb)评估HBV感染的患病率,并确定定期接受血液透析患者HBV感染的潜在危险因素。
本研究纳入80例定期接受血液透析且无急慢性HBV感染的患者。他们于2016年6月至2017年6月从也门萨那市的透析单位选取。乙肝表面抗原和乙肝表面抗体阳性的患者被排除在本研究之外。在每次血液透析前采集血样,并检测HBV的血清学标志物。采用酶联免疫吸附测定法检测HBcAb,采用聚合酶链反应检测HBV-DNA。
4例患者(5%)检测到HBV-DNA,38例患者(47.5%)检测到HBcAb。定期接受血液透析的患者中,HBV-DNA与HBcAb之间存在显著关联。
HBcAb检测呈阳性的患者应接受额外的HBV-DNA检测,以便准确筛查HBV并防止其他患者感染。